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Intravenous Formulation of 
HET0016 Decreased Human 
Glioblastoma Growth and 
Implicated Survival Benefit in Rat 
Xenograft Models
Meenu Jain1, Nipuni-Dhanesha H. Gamage2, Meshal Alsulami1, Adarsh Shankar1, 
Bhagelu R. Achyut1, Kartik Angara1, Mohammad H. Rashid1, Asm Iskander1, Thaiz F. Borin1, 
Zhi Wenbo3, Roxan Ara1, Meser M. Ali2, Iryna Lebedyeva4, Wilson B. Chwang2, Austin Guo5, 
Hassan Bagher-Ebadian2 & Ali S. Arbab1
Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016 is a selective 
CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. Therefore, to 
explore novel treatments, we have generated an improved intravenous (IV) formulation of HET0016 
with HPßCD and tested in animal models of human and syngeneic GBM. Administration of a single 
IV dose resulted in 7-fold higher levels of HET0016 in plasma and 3.6-fold higher levels in tumor at 
60 min than that in IP route. IV treatment with HPßCD-HET0016 decreased tumor growth, and altered 
vascular kinetics in early and late treatment groups (p < 0.05). Similar growth inhibition was observed in 
syngeneic GL261 GBM (p < 0.05). Survival studies using patient derived xenografts of GBM811, showed 
prolonged survival to 26 weeks in animals treated with focal radiation, in combination with HET0016 
and TMZ (p < 0.05). We observed reduced expression of markers of cell proliferation (Ki-67), decreased 
neovascularization (laminin and αSMA), in addition to inflammation and angiogenesis markers in the 
treatment group (p < 0.05). Our results indicate that HPßCD-HET0016 is effective in inhibiting tumor 
growth through decreasing proliferation, and neovascularization. Furthermore, HPßCD-HET0016 
significantly prolonged survival in PDX GBM811 model.
Glioblastoma (GBM) is a hypervascular malignant tumor with poor prognosis1,2. Because of hypervascularity, 
anti-angiogenic therapies (AATs) targeting the vascular endothelial growth factor (VEGF) and VEGF receptor 
(VEGFR) axis have been attempted in clinical trials, but the results have not been encouraging3. Moreover, our pre-
clinical studies in a rat model of human GBM also showed resistance to the treatment of receptor tyrosine kinase 
inhibitors (RTKIs) and resulted in paradoxical enhancement of neovascularization and tumor growth4,5. Therefore, 
we need an agent that will decrease tumor growth and neovascularization with reduced resistance to therapy.
Recently, studies have shown the role of N-hydroxy-N’-(4-butyl-2 methylphenyl) formamidine (HET0016), a 
highly selective inhibitor of 20-hydroxy arachidonic acid (20-HETE) synthesis involving enzymes of the CYP4A 
and CYP4F families, in inhibiting tumor angiogenesis, proliferation, migration, and regulation of CD133+ /
CD34+ EPCs6–8. HET0016 was able to inhibit angiogenic responses to several growth factors as well as angio-
genesis in gliosarcoma and in the cornea induced by implanted human U251 GBM cells9,10. Our previous study 
in breast cancer also showed decreased tumor growth after treatment with HET00168. In previous studies of 
GBM, HET0016 was prepared in cremophor and DMSO that was administered either orally or intraperitoneally 
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(IP). However, there was limited success in controlling the glioma due to low bioavailability11. In the present 
study, we optimized a condition to make IV formulation of HET0016 with 2-Hydroxypropyl Beta Cyclodextrin 
(HPßCD) to improve bioavailability and deliver an effective dose of the drug to the tumor site, especially in the 
hypervascular and hypoxic areas of GBM. HPßCD is a derivative of β -cyclodextrin that has been extensively used 
as a drug delivery vehicle and recently, FDA has approved the use of HPßCD as a treatment for Niemann Pick 
Type C disease12,13. The exploitation of HPßCD as delivery vehicle in GBM may be beneficial due to the porosity 
of the tumor vasculature, an enhanced permeability and retention (EPR) effect and reduced off target effects in 
the tumor neovasculature14. Moreover, due to smaller size (< 1 nm) of the HPßCD encased drug, excess drug can 
be cleared rapidly through kidneys. Therefore, we believe that the use of HPßCD as a drug delivery system for 
delivering HET0016 in GBM will not have any detrimental effect.
In the current rat xenograft model of GBM, we have performed magnetic resonance imaging (MRI) studies, 
which help in analysis of changes in tumor vascular physiology, tumor size, backward transfer constant (kep), 
tumor plasma volume (vp), vascular permeability (forward transfer constant, Ktrans), extravascular and extracel-
lular space volume interstitial space volume fraction (ve)15. In addition to MRI, we have also evaluated changes in 
histological parameters, effect on survival and signaling pathways following HET0016 treatment. These parame-
ters may allow for a better understanding of the physiological characteristics of the regional tumor environment 
and vascularity after HET0016 treatment.
The main purposes of the study are (1) to determine whether HPßCD can be complexed with HET0016 within 
reasonable period of time (practical kitchen chemistry) to obtain a water soluble formulation that can be admin-
istered intravenously, (2) to investigate the effects of IV administration of HET0016 on human and syngeneic 
GBM tumor growth, and survival in patient derived GBM animal models, vascular parameters, histology, and (3) 
to identify critical signaling pathways inhibited by HPßCD-HET0016, when administered through IV in the rat 
GBM xenograft model.
Results
IV formulation of HET0016 with 30% cyclodextrin. IV formulation of HET0016 using 30% HPβ CD 
(in solution with water) was stable both at 4 °C and room temperature for an extended time without any precip-
itation of HET0016 (Fig. 1a shows the structure of HET0016 with cyclodextrin). IV administration of 5-day old 
complex solution did not cause any immediate or late detrimental effect on health of the animals. There was no 
change in the mass-spectrometric profile between the naked and HPβ CD-HET0016 complex alone or mixed with 
plasma or cell lysate (Fig. 1b). All profiles showed the molecular weight of HET0016 (complex or naked) between 
206 and 207 kDa with retention and elution time of 2.9 minutes.
Figure 1. Preparation of HPßCD-HET0016 complex (a) Structure of HET0016 and HPßCD is shown. HPßCD 
resembles a shell and it can encase any deliverable drug. To prepare the IV formulation of HET0016, it was first 
dissolved in DMSO and added to 30% HPßCD prepared in water. The bucket like structure of HPßCD with 
hydrophilic exterior helps encase HET0016 and delivers to the target area. (b) Mass spectrometry of HET0016 
in DMSO (left panel), HET0016 complex in plasma (middle panel). HPßCD-HET0016 complex in tissue lysate 
(right panel). Plasma and tissue lysate was collected from the rats bearing glioma and injected with single dose 
of HPßCD-HET0016 for evaluation of pharmacokinetics.
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HET0016 levels in plasma and tumor tissue. Rats were orthotopically implanted with U251 cells and 
allowed to form the tumor. HET0016 was administered to rats IV and IP as a single dose and sacrificed for phar-
macokinetics at different time points. A total of 12 rats were serially euthanized for the measurement of HET0016 
levels in plasma and brain tumor tissue at 0, 5, 30, 60, 180 min and 24 h (1440 min) after single IV and IP HET0016 
administration (10 mg/kg) (n = 2–4 per time point) and analyzed by LC-MS/MS as described in pharmacokinet-
ics section in material and methods. The level of HET0016 was 7-fold higher in plasma in the group of IV route at 
5 min and 60 min time point (105042 and 36880.18 ng/ml) as compared to the IP group (15938.1 and 4773.0 ng/
ml) (p < 0.005) (Fig. 2a). The plasma concentration suggests there was rapid elimination of HET0016 with a 
half-life of approximately 45 min for both the IV and IP groups. The concentration of HET0016 in tumor tissue in 
the IV group was much higher than that of the IP group at 60 min (9251 ng/g vs 325 ng/g) and 24 h (42.7 ng/g vs 
7.4 ng/g) (p < 0.01) (Fig. 2b). There was no significant difference at middle time point at 180 min.
Effect of HET0016 on tumor growth and vascular parameters. Rats were orthotopically implanted 
with U251 cells and allowed to form tumor for 8 days. After day 8, animals were treated with HET0016 and fol-
lowed up for 21 days. A detailed schema of treatment schedule is shown in Fig. 3. Treatments on the same day and 
seven-day waiting period were chosen to mimic the post-surgical cases and post diagnosis of GBM, respectively, 
as described previously4. Tumor growth was measured by in vivo MRI. IV administration of HET0016 signifi-
cantly reduced the tumor growth (in delayed [day 8–21] treatment) compared to that of vehicle treated animals 
(p < 0.001) (Fig. 4a) and there was reduced growth with early (day 0–21) treatment although significant difference 
was not achieved. When compared to the IP administered treatment, tumor growth was reduced only with early 
IP treatment, although significant difference was not achieved (Fig. 4a). However, when all groups were com-
pared, significant (p < 0.005) reduction of tumor volume was found for delayed IV treatment group compared to 
the vehicle and delayed IP HET0016 treated groups (Fig. 4a).
Vascular parameters were evaluated to gain information about the vascular kinetics of the tumor environment. 
Delayed IV HET0016-treated animals showed significantly increased blood flow, which may indicate normali-
zation of blood vessels causing enhanced flow although there was no significant difference in blood flow (rCBF) 
among the IP and early IV treated groups (Fig. 4b). As expected, late IP or IV HET0016 treated animals showed 
significantly lower vp (blood plasma pool), ve (extracellular space or interistial volume), Ktrans (forward permea-
Figure 2. Pharmacokinetics of HPßCD-HET0016 in plasma and tissue after IV and IP dose administration 
in rat glioblastoma model. The concentrations of HET0016 in plasma or tissue versus time post dose 
administration in rat model are shown. Blood samples were obtained for 0–24 hrs after dose administration. 
Plasma and tissue HET0016 concentrations were determined by LC-MS/MS after liquid phase extraction. Each 
data point is presented as the mean concentration ± SEM (n = 2–4). Concentration of HET0016 in plasma  
(a) and tumor tissue (b) after a single HET0016 (10 mg/kg) dose through IV and IP route. Significant values 
from t Student test and Mann-Whitney’s test are represented by *p < 0.05 in comparison to IV and IP doses in 
the same time point.
www.nature.com/scientificreports/
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bility transfer constant) compared to that of corresponding vehicle treated groups (p < 0.01) (Figs 4c and 5a–c). 
Both early IP and early IV groups also showed significantly lower vp compared to that of corresponding vehicle 
treated groups (Fig. 4c). As rCBF analysis showed higher blood flow (Fig. 4b), it is expected that normalized ves-
sels will have less Ktrans (Fig. 5a) compared to that of neovessels. Therefore, the blood plasma pool (vp) would be 
reduced in tumors with normalized vessels (Fig. 4c). When the extravascular extracellular space volume (ve) was 
compared, both early and delayed IV HET0016- treated groups showed significantly decreased ve compared to 
that of vehicle and IP-treated groups (Fig. 5c). There was no difference in kep (backflow transfer) between the IP 
and IV group of animals (Fig. 5b). We also evaluated the blood chemistry to determine the toxicity following 0–21 
days of treatment with either vehicle, IV formulated or IP HET0016 in GBM xenografts. We did not observe sig-
nificant changes on liver function, renal function, important enzymes, pancreas, and lipid profile after HET0016 
treatment in IP and IV groups (Supplementary Table 1).
Proliferation (Ki67), Micro Vessel Density (MVD), Smooth muscle Actin (αSMA), extracellular 
and extravascular space (EES). Brains were removed from the rats (U251 xenograft model) following 
euthanasia and prepared for immunohistochemistry as described in material and methods. Tumor section in the 
early and delayed IV or IP treatment and vehicle groups were stained for Ki67, which is a marker of cellular prolif-
eration. Ki67 positive and negative tumor cells were counted within the tumor areas. Ki67 positive cells along the 
endothelial lining were omitted during counting and calculation of the proliferative cells. In IP treatment groups, 
only delayed treatment showed reduced proliferation but not significant (Fig. 6a,c). However, in IV treatment 
groups, significant decreased proliferation was observed in both the early and late treatment groups as compared 
to corresponding vehicle groups (Fig. 6b–d).
Tumor tissues were also stained for laminin to analyze for microvessel density (MVD). Laminin, a basement 
membrane glycoprotein, is found under the endothelium, encasing the pericytes and smooth muscle cells in the 
vessel wall and has been shown to be an excellent marker for blood vessels in the brain. Tumor sections were 
stained with laminin antibody and images from the positive area were taken at 10x and 20x and counted for 
a number of vessels. We found no significant difference in expression of laminin among the IP-treated groups 
(Fig. 7a–c, top left panel). However, there was significant reduced expression of laminin with lower number of 
vessels (3–50 fold less) in the IV treatment group especially around the rim of tumor as compared to vehicle 
(p < 0.01) (Fig. 7d–f top right panel). We also performed α SMA immunostaining to demonstrate the effect on 
vessels in pericyte area around tumor periphery and found there was a significantly smaller number of ves-
sels with reduced expression of α SMA in the IV treatment group as compared to vehicle (p < 0.02) (Fig. 7e,f). 
However, no such differences were detected in the early and delayed IP-treatment groups (Fig. 7b,c).
Differences in the area of extracellular and extravascular space were also analyzed by using H&E stained 
images from the IP and IV groups using the color thresholding method as described earlier5. There was no dif-
ference observed among IP treatment groups as compared to vehicle (Supplementary Figure 2a,b top panel). 
However, we found a threefold reduction in the extracellular and extravascular space in the IV-treated groups 
(both early and delayed) as compared to vehicle (p < 0.01) (Supplementary Figure 2c,d bottom panel).
Reduced expression of cell proliferation, inflammatory and angiogenic proteins were detected 
in glioma treated with HET0016. A protein array was performed using tissue lysates for angiogenic 
related growth factors using a membrane based protein array kit. Supplementary Figure 3 shows the expres-
sion of important proteins related to angiogenesis among the control, early and delayed IV treatment groups. 
Pro-angiogenic proteins such as VE-cadherin (vascular endothelial cadherin-vasculogenesis), bFGF (basic 
fibrobalst growth factor), IL-8 (chemokine CXCL8) and MCP-1 (a CCL2 ligand) were significantly downregu-
lated in the delayed IV treatment group while expression of anti-angiogenic proteins such as Tie-2, angiostatin 
and angiopoietin-2 was increased in the delayed treatment group (day 8–21; Supplementary Figure 3a) as com-
pared to control (p < 0.03). In the early treatment group, expression of proteins, such as MCP-1, angiostatin 
and angiopoietin-2 followed a similar trend, indicating a significant effect of the treatment, particularly on the 
factors secreted or expressed by endothelial and inflammatory cells. Western blot was performed to determine 
the expression of proteins related to cellular proliferation (p-ERK), survival (p-AKT), inflammation (COX-1/2), 
arachidonic acid metabolism (CYP4A11), signal transducers and activators of transcription (p-STAT1). We also 
Figure 3. Schematic representation of treatment schedule. U251 glioma cells were implanted orthotopically 
in rat’s brain and treated with HPßCD-HET0016 as described in material and methods.
www.nature.com/scientificreports/
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Figure 4. HPßCD-HET0016 reduces tumor growth and vascular parameters in rat glioblastoma model.  
(a) Representative post contrast T1-weighted images from in vivo imaging of rat with glioma show tumor size 
from different groups of animals. Semi-quantitative analysis shows significantly reduced tumor volume in 
animals that received HET0016 from day 8 and continued for 2 weeks (n = 5 to 8). (b) Relative cerebral blood 
flow maps created from arterial spin labeling techniques. Semi-quantitative analysis (bar graphs) indicates 
higher flow in IV HET0016-treated groups (started on day 8) compared to that of vehicle-treated group  
(n = 5 to 8). (c) Tumor plasma volume maps and semi quantitative analysis are shown. Both IV and IP 
treatment with HET0016 caused a significant decrease in tumor plasma volume (vp) compared to vehicle and 
corresponding IP-treated groups. Each group is represented as the mean of the total measurable MRI sections 
from animals of each group (n = 5–8 animals but 7–16 sections). Significant values from ANOVA test followed 
by Fisher’s exact test are represented by *p < 0.05 compared to the corresponding vehicle group. An outlier data 
point (from a single MRI section) was removed as described in our material and methods.
www.nature.com/scientificreports/
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Figure 5. HPßCD-HET0016 influences vascular parameters in rat glioblastoma model. MRI images from  
in vivo rat imaging show significant changes in vessel permeability (Ktrans) (a), and ve (interstitial space volume)  
(C) but no changes in kep (backflow rate constant) (b) in early and delayed treatment in IV groups. Significant 
values from ANOVA test followed by Fisher’s exact test are represented by * and #p < 0.05 compared to (*) 
vehicle 8–21 vs IV HET 8–21 and vehicle 0–21 vs IV HET 0–21, and (#) IP HET 8–21 vs IV HET 8–21 and IP 
HET 0–21 vs IV HET 0–21. Each group is represented as the mean of the total measurable MRI sections from 
animals of each group (n = 5–8 animals but 7–16 sections), analyzed by MRI at 0.5 μ m thickness in a range up to 
7–16 viewed slices of each animal.
www.nature.com/scientificreports/
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determined the expression of, HIF-1α , EGFR, VEGF, MMP-2 (angiogenesis) and p-NFKB (inflammation), to 
investigate the effects of IV administered HET0016 on the rat model of GBM. We observed reduced levels of 
COX-1, CYP4A11, p-ERK, p-AKT, p-STAT1, HIF1α , EGFR, VEGF, MMP-2 and p-NFKB proteins in tumors 
obtained from both IV treatment groups as compared to vehicle (Supplementary Figure 3b), which confirms the 
influence of HPβ CD-HET0016 on cell proliferation, migration, and inflammation pathways.
Effect of HET0016 on survival in GBM811 and HF2303. We evaluated the effect of HET0016, TMZ 
alone or in combination with radiation on survival in PDX derived tumor model of GBM811 and HF2303. First, 
we tested the effect of treatment in vitro 3D culture model (HF2303) and found that the treatment with HET0016 
or TMZ alone or combination showed the inhibition of the growth of neurospheres Fig. 8a). Similar studies were 
planned in vivo model and we observed that HET0016 treatment alone or in combination with TMZ in irradiated 
tumor bearing animals resulted in reduced tumor growth and prolonged survival in both GBM811 (p < 0.004) 
and HF2303 PDX models (p = 0.18) (Fig. 8b). The overall survival in GBM811 model was prolonged to 26 weeks 
after the treatment with HET0016 plus TMZ and radiation, while control animals (supercontrol and irradiated 
only control) survived only for 10 weeks similar to the clinical setting (Fig. 8c). The cumulative survival was 100% 
for HET0016 plus TMZ combination group as compared to 66% for TMZ alone, 33% for HET0016 alone at 26 
weeks until the end of the study without demonstrating any evidence of recurrence (Table in Fig. 8d). Therefore, 
the current study provides evidence that combination therapy (HET0016 + TMZ) with irradiation can improve 
survival in GBM. In the second PDX model of HF2303, the HET0016 treatment alone and in combination with 
TMZ, resulted in reduced tumor volume and prolonged survival of 26 weeks vs. only 17 weeks of irradiated con-
trol (p < 0.10). The cumulative survival was 25% for both HET0016 plus TMZ combination group and HET0016 
alone group at 26 weeks as compared to 0% in radiation only group (p < 0.18). Thus, data indicates combination 
treatment with HET0016 plus TMZ and irradiation resulted in better survival benefit as compared to radiation 
alone. Overall, the response was better in GBM811 model than HF2303 model and may be attributed to difference 
in growth and genetic characteristics. We also measured the presence of 20-HETE and MGMT in different glioma 
cells (GL261, U251, HF2303 and GBM811) and GBM811 showed comparatively lower amount of 20-HETE and 
methylguanine DNA methyltransferase (MGMT) levels (Supplementary Figure 5 and 6), which may indicate 
better treatment results following HET0016, radiation and TMZ in GBM811 PDX model16,17.
Figure 6. HPßCD-HET0016 treatment results in reduced proliferation, migration in rat glioblastoma 
model. (a,b) Ki-67 immunohistochemical staining was done as a marker of proliferation in tumor tissues. 
Rats treated with HET0016 starting on day 8 showed significantly fewer proliferative cells in the tumor in the 
IV group compared to the IP group. (c,d) Bar graphs represent the proportion of Ki67 positive tumor cells 
compared to total number of tumor cells in tumor area of each group. Images were taken in 40x magnification. 
The brown nuclei color shows the positive labelling cells. Statistically significant differences were verified by 
ANOVA followed by Bonferroni’s test. *p < 0.05 in comparison to the respective vehicle group.
www.nature.com/scientificreports/
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Effect of IV HET0016 on GL261 syngeneic GBM. We also assessed the effect of IV HET0016 on tumor 
growth in syngeneic model of GBM using GL261 cell line. All animals underwent MRI and tumor volume 
was measured from the MRI images. There was significantly reduced tumor volume in animals treated with 
IV HET0016 (54.33 ± 12.37 mm3) compared to that of vehicle treated animals (131.70 ± 19.45 mm3) (p < 0.007) 
(Supplementary Figure 1).
Discussion
Despite the availability of current chemotherapy and targeted therapies in GBM (e.g. temozolomide and bevaci-
zumab), not many therapeutic benefits have been achieved due to target developing drug resistance18. Most ther-
apies have produced a decrease in tumor growth during early stages of treatment followed by aggressive tumor 
recurrence. Mu et al. previously developed water-soluble IV formulation of HET0016 which rapidly penetrated in 
the rat normal brain and inhibited the formation of 20-HETE after cerebral ischemia19. Here, we have developed 
an improved IV formulation of HPßCD-HET0016 that dissolves in 2–3 min compared to the 48 hrs as reported 
by Mu et al. IV administration of HPßCD-HET0016 in a rat model of human GBM significantly reduced tumor 
growth in developing or developed tumors as compared to IP HET0016 treatment. It appears that the IV formu-
lation facilitated increased delivery of HET0016 to the hypervascular and hypoxic tumor sites, due to EPR effects. 
Moreover, the effect of IV HET0016 was not cell specific and showed similar reduced tumor growth in syngeneic 
Figure 7. HPßCD-HET0016 treatment results in reduced neovascularization in rat glioblastoma 
model. Laminin and α SMA immunohistochemistry staining was done in tumor tissues to determine the 
neovascularization (a,b,d and e) Representative images from brain tumor tissues are shown at 10x and 20x 
from the IP (left panel) and IV (right panel) groups. Red arrows indicate blood vessels. Four areas on the tissue 
section were selected and the number of vessels counted. (c and f) Laminin and α SMA quanfication. Each 
bar represents an average of four areas and was estimated in multiple samples from each group (n = 2–4). 
Significant difference is indicated by *p < 0.05 compared to the respective vehicle group.
www.nature.com/scientificreports/
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tumor (GL261) models. The distribution profile of HPßCD-HET0016 formulation showed better bioavailability 
and retention in tissue with a higher brain to plasma ratio in the IV treatment group as compared to the treatment 
with IP preparation. The findings suggest that the IV formulation or encapsulation of HET0016 in a non-toxic 
delivery system may have the benefits of increased half-life (protect the drug from degradation during circulation 
and early clearance), lower toxicity, enhanced EPR effect over the IP preparation and improved the therapeutic 
index14. Furthermore, enhanced accumulation of macromolecular drugs in tumor tissues can occur as compared 
to normal tissue due to impaired lymphatic drainage and porous blood vessels in GBM with abnormal molec-
ular and fluid transport dynamics20,21. The effect of enhanced delivery of IV HET0016 is supported by vascular 
parametric analysis in MRI studies. Vascular parametric analysis supported the effect of the drugs, where the IV 
formulation decreased vascular permeability (Ktrans), tumor blood volume (vp), and extracellular extravascular or 
interstitial space volume (ve) but increased the blood flow to the delayed treated tumors in GBM.
TMZ is widely used alkylating agent for the treatment of primary as well as recurrent GBM. Effect of TMZ 
requires functional DNA mismatch repair (MMR), low levels of methylguanine DNA methyltransferase (MGMT) 
and DNA repair genes16,22,23. Unfortunately, majority of the primary and recurrent GBMs have unmethylated 
or active high level of MGMT, which make TMZ treatment unresponsive17,24,25. We evaluated the synergistic 
effect of HET0016 alone or in combination with TMZ on the survival of animals treated with 30 Gy irradiation 
in patient-derived xenograft models (PDX) (GBM811, HF2303) (treatment schedule shown in Supplementary 
scheme). After Administration of HET0016 alone and in combination with TMZ and radiation in GBM811 and 
HF2303 models for 6 weeks resulted in good response and tumor did not relapse until 6 months (endpoint of 
the study). Therefore, HET0016 plus TMZ combination may prolong survival and reduce therapy resistance. The 
synergistic effect may be due to the role of HET0016 in sensitizing the action of TMZ and irradiation by reducing 
DNA repair mechanisms. Our preliminary study indicated that HET0016 administration resulted in down reg-
ulation of DNA repair genes (unpublished preliminary data, Supplementary Fig. 4). The continuous exposure of 
Figure 8. Treatment with HET0016 and TMZ prolongs survival in PDX models. (a) Treatment with 
HET0016 and TMZ inhibit neurospheres growth in vitro: HF2303 was treated with HET0016 and TMZ alone 
(100 μ M), in combination with TMZ and followed up for 14 days. (b) HF2303 and (c) GBM811 show the 
effect of HET0016 and TMZ on survival rate of the mice in groups 1, 2, 3, 4 and 5 of treatment schedules (as 
described in Material and Methods) were evaluated from the first day of treatment until death. X-axis represents 
cumulative survival time in weeks. Table in Fig. 8d summarize the details of duration in weeks and % survival. 
Athymic nude rats were implanted orthotopic with HF2303 and GBM811. Six to ten weeks after implantation, 
rats were randomized into five treatment groups receiving PBS, radiation, HET0016, TMZ, HET0016 plus TMZ 
for another 6 wks, as described in Materials and Methods. #The animals were not included due to the technical 
difficulty. Significant difference is indicated by *p < 0.05 vs irradiation and super-control, $p-value was 0.18 vs 
irradiation control, achieved by Kaplan Meier analysis and Log-rank test.
www.nature.com/scientificreports/
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cellular DNA to potentially harmful environmental and internal insults necessitates redundant and overlapping 
DNA repair mechanisms26. Therefore, successful destruction of GBM tumors may require a combined approach 
utilizing standard treatments in combination with inhibition of DNA repair pathways.
The anti-tumor effect of HPßCD-HET0016 was supported by decreased tumor cell proliferation, migration, 
and neovascularization. There was a clear reduction in the number of Ki67 + cells in the IV treatment groups as 
compared to IP groups. The reason for observing the significant reduced proliferation in IV treatment groups 
may be that HET0016 is effective in preventing the regrowth of established tumor due to increased bioavailability 
following IV administration. We also believe established tumor has developed-neovascularization and leaky ves-
sels, which allow EPR effect to be more pronounced in groups treated with IV formulated HET0016. In addition, 
we suggest that the effect of HET0016 on tumor growth may be attributed to the reduced basic fibroblast growth 
factor expression (bFGF or FGF-2) after early and delayed treatment. bFGF is a potent mitogen that maintains 
cancer cell stemness and leads to drug resistance by enhancing the blood-brain-barrier function of endothelial 
cells27,28. These results are supported by an earlier study of Guo et al.29 which showed chronic in vivo admin-
istration of HET0016 (IP, 10 mg/kg/day) reduced the volume of 9 L gliosarcoma, accompanied by mitotic and 
vascularization reduction.
GBM tumor vessels are tortuous, disorganized, highly permeable, decreased pericyte coverage and a solid 
basement membrane structure30,31. We found overall fewer vessels in both early and delayed IV treatment group, 
with reduced EES, laminin, and α SMA staining, especially at the invasive margin of the tumor indicating the role 
of HET0016 in inhibiting the growth of new blood vessels. These observations were supported by a published 
report that suggested that the pericyte line around new endothelial cells sprouts from tumor vessels, play a role 
in blood vessel growth, and is suggested to be a potential target in AAT therapy32. In addition, this is further 
supported by a high expression of angiopoietin-2, Tie-2 molecules and reduced VE-cadherin expression, which 
is associated with pericyte endothelium suggesting an effect of HET0016 on vascular development and stabil-
ity33. We suggest that HPßCD-HET0016 has a primary effect on blood vessels, which by normalization increased 
the bioavailability of drug to the hypoxic tumor sites. MRI vascular parametric analysis also correlates with 
immunohistochemistry; especially the normalization of vessels in the IV delayed treatment groups that resulted 
in decreased permeability (Ktrans) and overall reduced plasma volume fraction (vp). The treatment also caused 
decreased EES volume indicated by decreased ve, which is also validated in H&E histological analysis. Similarly, 
Guo et al also showed normalization of vessels in 9 L tumor following HET0016 treatment10.
In our study, we observed that HET0016 reduced expression of the pro-angiogenic proteins but increased the 
expression of anti-angiogenic proteins expression to achieve equilibrium to reduce tumor growth. Expression 
of pro-angiogenic factors such as IL-8, MCP-1, VEGF and SDF-1α were decreased, while expression of inhibi-
tors of the angiogenic process such as angiostatin, angiopoietin-2/Tie-1, and Tie-2 proteins were increased after 
HET0016 treatment. Recently, a study in triple negative breast cancer showed a similar effect of IP HET0016 on 
pro-angiogenic factors8. We observed that HPßCD-HET0016 reduced IL-8 expression. IL-8 has recently been 
shown to be a critical factor in regulating cancer cell stemness and invasion, and higher expression was associated 
with poor survival and therapy resistance in glioma34. Moreover, HET0016 treatment reduces the expression of 
MCP-1 and SDF-1α , key chemokines responsible for trafficking and activation of monocytes/macrophages and 
have been involved in inflammation and angiogenesis35. MCP-1-induced angiogenesis has been reported to be 
mediated through up-regulation of HIF-1α and subsequent activation of VEGF35. Therefore, HPßCD-HET0016 
may be acting as an inhibitor of inflammation and angiogenesis growth responses in GBM tumor cells through 
regulating HIF-1α and VEGF. Interestingly, there were less hypoxic areas in HPßCD-HET0016-treated tumors as 
shown by reduced HIF-1α protein expression. Reduced HIF-1α expression also resulted in low VEGF expression 
after HPßCD-HET0016 treatment. VEGF signaling and angiogenesis and highly affected by HIF-1α levels and 
regulates endothelial cell proliferation, migration, and permeability of blood vessels. Studies have shown high 
expression is correlated with increased metastases, vasculature, and tumor recurrence28. These findings suggest 
that HPßCD-HET0016 regulated the expression of pro-and anti-angiogenic factors to achieve the balance in the 
maintenance of the tumor microenvironment8.
In the current study, we studied effect of HPßCD-HET0016 treatment in the arachidonic acid metabolism 
pathway. Previously, HET0016 has been shown to have an effect on expression of CYP4A enzymes. In present 
study, we found HET0016 was able to reduce the protein expression of CYP4A11 and COX-1, thereby influencing 
inflammation, angiogenesis, and MAPK signaling in GBM36,37. Previous studies have also documented a similar 
role of HET0016 in glioma, gliosarcoma, lung, and breast cancers10,29,38. A study in colon cancer suggested com-
bination therapy of rofecoxib and HET0016 might be a new treatment that can improve the anti-tumor efficacy of 
rofecoxib alone39. In addition, we also investigated role of p-NFκ B as marker of inflammation and proliferation. 
Previous studies have shown a pro-survival role for p-NFκ B in glioma and an association with chemo resistance40. 
We demonstrated reduced levels of p-NFκ B after HET0016 treatment suggesting an anti-proliferative effect in 
glioma.
Previous study have shown that GBM has frequent overexpression of EGFR, which leads to activation of 
the P13/Akt pathway, associated with adverse clinical outcome and has been suggested to be a therapeutic tar-
get41–43. We showed that HPßCD-HET0016 repressed the expression of EGFR, ERK, and Akt, a target of MEK. 
We also determined expression of p-STAT1, a tumor suppressor protein involved in the p38/MAPK pathway in 
response to IFN-α and stress. Higher expression of p-STAT1 was shown to be associated with poor prognosis 
in glioma and depletion of IRF1/STAT1 signaling has been reported to increase the efficacy of anti-VEGF (bev-
acizumab) therapy in a glioma xenograft model44–46. We found that HPßCD-HET0016 treatment also reduced 
the levels of pSTAT1, indicating HET0016 can improve overall prognosis in glioma. In summary, we have estab-
lished a highly soluble HPßCD-HET0016 complex for IV administration that reduced GBM growth, normal-
ized vasculatures, decreased permeability, and EES volume both in established and growing tumors through 
enhanced bioavailability compared to conventional IP HET0016 preparation. Our results showed that HET0016 
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in combination with TMZ and radiation enhanced the anti-tumor efficacy and prolonged survival in GBM xen-
ograft models as compared to TMZ alone. Anti-tumor properties of HPßCD-HET0016 resulted in decreasing 
proliferation, hypoxia, migration, stemness, and vasculatures in glioma by altering the balance of pro-angiogenic 
and anti-angiogenic balance, PI3K/Akt, p38/MAPK and inflammation pathways (Summary model in Fig. 9). 
Therefore, HPßCD-HET0016 could be tested in clinics to explore combination therapies with TMZ or radiother-
apy for GBM.
Materials and Methods
Ethics statement. Animal experiments were performed according to the NIH guidelines and the experi-
mental protocol was approved by the Institutional Animal Care and Use Committee of Henry Ford Health System 
and Augusta University (formerly Georgia Regents University) (Approval number: 2014–0625). All animals were 
kept under pathogen-free conditions at room temperature (21 to 25 °C) with exposure to light for 12 hours and 
12 hours in the dark. Food and water were offered ad libitum. Body weight was measured twice weekly as an 
indicator of overall animal health. All surgeries were performed under ketamine - xylazine anesthesia, and efforts 
were made to minimize suffering. Euthanasia for the moribund animals was performed in a CO2 chamber.
Chemicals. HPßCD (2-hydroxy Propyl-β -Cyclodextrin) was purchased from Sigma-Aldrich (St. Louis, MO), 
cell culture media was from Thermo Scientific (Waltham, MA), and fetal bovine serum was purchased from 
Hyclone (Logan, Utah). HET0016 was obtained from Dr. JR Falck of UT Southwestern University, Texas, and 
also synthesized by Dr. Iryna Lebedyeva in the department of Chemistry and Physics, Augusta University with a 
purity of more than 97%. Cell culture grade DMSO was purchased from Fischer Scientific (PA). Blood chemistry 
profiles and electrolytes were determined Using third party vendor (Antech Diagnostic).
Tumor cells. Human glioma U251 cell line was obtained from Dr. Steve Brown of Henry Ford Health System. 
The cell line was authenticated in July 2014 using the STR profiling method. GL261 syngeneic (C57BL/6 mouse 
derived) GBM cell line was obtained from Dr. Ted Johnson (Augusta University) and was authenticated in 2016. 
The cell line, U251 was grown in high glucose (4.5 g/L) Dulbecco’s modified eagles medium (DMEM) and GL261 
in RPMI (Roswell Park Memorial Institute) (Thermo Scientific), supplemented with 10% fetal bovine serum 
(FBS), 2 mM glutamine and 100 U/ml penicillin and streptomycin at 5% CO2 at 37 °C in a humidified incubator. 
Figure 9. Summary and hypothetical model. Tumors consist of an abnormal vasculature, composed mainly 
of immature vessels with increased permeability. The less densely packed cells allow drugs or complexes 
to accumulate in tumor tissue. Treatment with HPßCD-HET0016 leads to reduced expression of α SMA 
and increased expression of angiopoietin-2 and Tie-2, which may lead to reduced tumor vasculature that is 
inadequate to support tumor growth and may lead to tumor dormancy. Our results suggest that HET0016 
reduces cancer cell growth, invasion, and vasculature by reducing the expression of signaling molecules in the 
MAPK, PI3K/AKT, and inflammation pathways.
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Patient derived GBM cells (HF2303) was obtained from Dr. Tom Mikkelsen’ s lab at Henry Ford Hospital and 
was grown in neurosphere medium (NM), composed of DMEM/F-12 supplemented with N2 (Gibco), 0.5 mg/ml 
BSA (Sigma), 25 μ g/ml gentamicin (Gibco), 0.5% antibiotic/antimycotic (Invitrogen), 20 ng/ml basic fibroblast 
growth factor, and 20 ng/ml EGF (Peprotech). Cells were maintained in culture for up to passage 10 (low passage). 
Patient derived PDX GBM cells, GBM811 was obtained from North Western University and was propagated in 
immunocompromised NOD-SCID mouse and tumor was disintegrated into cell suspension at the time of tumor 
implantation in nude rats.
Intraperitoneal (IP) formulation of HET0016. For IP formulation, 2 mg of HET0016 was dissolved in 
1 ml of solution containing 80% PBS, 10% of dimethyl sulfoxide (DMSO) (Sigma, St. Louise, MO, USA) and 10% 
cremophor (Sigma, St. Louise, MO, USA). The mixture was vortexed and sonicated until HET0016 was dissolved. 
Each rat received 10 mg/kg/day dose and the dose has been used according to previous publications10,11.
Intravenous (IV) formulation of HET0016 using HPßCD (2-hydroxy Propyl-B-Cyclodextrin). 
Previous published methods have used 48 hours incubation with continuous rotation to make a complex of 
HET0016 with HPßCD for the IV formulation19. Here, we describe a rapid and safe method to synthesize IV for-
mulation of HET0016 without using a sonicated water bath or long rotation. HPßCD has a bucket-like structure 
with hydrophilic outer shell but hydrophobic inner cavity (Fig. 1a). However, optimized conditions are needed 
to insert the drug into the HPßCD cage since HET0016 is a heat sensitive compound and can be degraded with 
long-term rotation at room temperature. HET0016 was dissolved in DMSO (2 mg/50 μ l) and was added slowly 
to a 30% HPßCD solution in sterile water (950 μ l) with continuous vortex, and the turbid solution became clear 
within 2–3 minutes. The final concentration of DMSO was 5%. We have tested mass-spectrometric profiles of 
HET0016 complexed with HPßCD as well as HET0016 dissolved in DMSO (Fig. 1b). The solution of HET0016 
in DMSO showed a peak at 2.9 min retention elution time, and it did not change when HET0016 was complexed 
or encapsulated with HPßCD.
HET0016 pharmacokinetics in plasma and tissue lysate. Twelve nude rats (RNU nu/nu) obtained 
from Charles River Laboratory (Frederick, MD) were used for pharmacokinetics studies. A single IV injection of 
HET0016 or vehicle (10 mg/kg) in 30% cyclodextrin or IP injection of HET0016 was administered to the animals 
in the respective groups. Animals were euthanized at multiple time points, and brain tumor tissue was collected 
(60, 180 min, 24 hrs). The details are provided in Supplementary methods.
Animal model and treatment schedules. Forty-eight nude rats (RNU nu/nu) weighing 140–150 grams 
obtained from Charles River Laboratory (Frederick, MD) were used in these experiments. Human glioma U251 
cells (400 k in 5 μ L), were implanted orthotopically at 3 mm to the right and 1 mm anterior to bregma according to 
published methods47. Following implantation, animals received treatment of HPßCD-HET0016 (IV, 10 mg/kg per 
day); an equivalent dose of IV HPßCD alone as a vehicle; HET0016 (IP, 10 mgkg/day), or an equivalent dose of IP 
vehicle alone for either two or three weeks. The details of animal model are described in Supplementary methods.
In vivo MRI and measurement of vascular kinetics. All animals underwent MRI, vascular kinetic, 
and tumor volume analyses as described previously on day 225 as depicted in Fig. 3. The details on methods are 
provided in Supplementary methods section.
Tumor volume analysis. Post contrast T1-weighted images were used to determine the tumor volume. At 
least two investigators, blinded to the various treatment groups, determined the volume by drawing irregular 
region of interest (ROIs) for all slices containing tumor. To calculate the exact volume, investigators summed up 
the number of slices and multiplied by the slice thickness.
Survival studies in PDX GBM models. Anti-tumor effects and survival studies were conducted in patient 
derived xenograft GBM model (PDX) using HET0016 as an adjuvant to the current treatment strategies of GBM 
(radiation and TMZ). Two different PDX models were developed using HF2303 (n = 11) and GBM811 (n = 13). 
Cells were suspended in PBS and 2 × 105 cells in 5 μ l were injected orthotopically into brain of each, 5–7-week-old 
nude rats, as described previously47–50. Prior to the start of treatment, animals underwent MRI at 6 weeks for 
GBM811 and 10 weeks for HF2303 before the start of treatment to confirm the presence of a 3 mm3 tumor. 
Thereafter, animals were randomly assigned to five treatment groups and details of the treatment are shown 
in Supplementary scheme. The five groups of treatment in the present study were as follows: (1) supercontrol; 
tumor bearing animals were treated with PBS (IV) twice weekly. (2) Irradiation control; tumor bearing animals 
received a single dose of 30 Gy radiation encompassing the tumor. (3) Irradiation + HET0016; following single 
dose of 30 Gy irradiation tumor bearing animals received IV HET0016 (10 mg/kg, 5 days/week, every other week 
for 6 weeks. (4) Irradiation + TMZ; following single dose of 30 Gy irradiation tumor bearing animals received 
oral TMZ (50 mg/kg, 2 days/week every other week for 6 weeks). (5) Irradiation + HET0016 + TMZ; follow-
ing single dose of 30 Gy irradiation tumor bearing animals received IV HET0016 plus oral TMZ for six weeks. 
HET0016 was given on 1st, 3rd and 5th weeks and TMZ was given on 2nd 4th and 6th week following irradiation. All 
animals (GBM 811 and HF2303) received 30 Gy of irradiation in a single fraction before the treatment of TMZ 
and HET0016 alone or in combination except the super-control group that did not go through irradiation or any 
other treatments. A single dose of 30 Gy radiation was given in an area encompassing the tumor using an X-ray 
based image-guided micro small animal radiation research platform from Gulmay Medical Inc. (SARRPTM, an 
Xstrahl company). All surviving animals underwent 2nd set of MRI following 6 weeks of treatments to determine 
the effects on the tumor volume. 3rd set of MRI was obtained from all surviving animals 4–6 weeks after the end 
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of the treatment. 4th set of MRI was also obtained from all surviving animals at the end of the studies (26 weeks 
following tumor implantation). All animals were checked for weight gain or loss at least 2 times a week from the 
day of tumor implantation. Any sign of morbidity was also noted. Survival was calculated from the day of tumor 
implantation until death. One hundred and eighty-three days after tumor implantation, the experiment was ter-
minated, and the surviving animals were sacrificed. All rats were autopsied at death to examine the antitumor 
efficacy of each treatment regimen. Our previous experience showed that HF2303 GBM bearing animals die by 
16–20 weeks and GBM811 tumor bearing animals die in 12–16 weeks if not treated.
Histopathology. Tissues were stained for proliferation (anti-Ki 67 antibody, Millipore, USA), human spe-
cific MHC-1 marker (anti-MHC-1 antibody, now HLA-A, Abcam), anti-laminin antibody (for blood vessels), and 
smooth muscle actin (SMA) for pericytes (anti-α SMA antibody abcam, USA) using standard immunohistochem-
ical procedure as described previously and included in Supplementary methods 8.
Statistical analysis. Comparison between drug and vehicle-treated groups was done by using Student’s 
t-test. When more than two groups were analyzed, we used ANOVA followed by Bonferroni test for normal 
distribution or Fisher’s exact test. All data were expressed as means ± SEM. P value of < 0.05 was considered sig-
nificant value in all tests. The criteria to exclude an outlier were the value outside of the range of mean ± twice the 
standard deviation (if necessary). Body weight, tumor volume, and survival were compared among PBS-treated, 
HET0016-treated, TMZ-treated, and HET0016 plus TMZ–treated groups. Kaplan Meier analysis was performed 
to determine the survival of the animals bearing PDX derived GBM and log rank was used to compare the sur-
vival between the two groups.
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